Eterna Therapeutics Inc (ERNA) - Total Assets
Based on the latest financial reports, Eterna Therapeutics Inc (ERNA) holds total assets worth $6.17 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check cash flow reinvestment rate of Eterna Therapeutics Inc to assess the company's total reinvestment commitment from operating cash flow.
Eterna Therapeutics Inc - Total Assets Trend (2006–2024)
This chart illustrates how Eterna Therapeutics Inc's total assets have evolved over time, based on quarterly financial data. Explore ERNA long-term investment intensity to see how much of total assets are deployed in long-term investments.
Eterna Therapeutics Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Eterna Therapeutics Inc's total assets of $6.17 Million consist of 44.6% current assets and 55.4% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 32.8% |
| Accounts Receivable | $437.00K | 8.3% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $2.04 Million | 38.8% |
Asset Composition Trend (2006–2024)
This chart illustrates how Eterna Therapeutics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Eterna Therapeutics Inc (ERNA) market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Eterna Therapeutics Inc's current assets represent 44.6% of total assets in 2024, a decrease from 60.5% in 2006.
- Cash Position: Cash and equivalents constituted 32.8% of total assets in 2024, up from 0.0% in 2006.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 38.0% of total assets, an increase from 0.0% in 2006.
- Asset Diversification: The largest asset category is goodwill at 38.8% of total assets.
Eterna Therapeutics Inc Competitors by Total Assets
Key competitors of Eterna Therapeutics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $8.59 Billion |
|
Cyclacel Pharmaceuticals Inc
NASDAQ:CYCC
|
USA | $4.40K |
|
Krystal Biotech Inc
NASDAQ:KRYS
|
USA | $1.40 Billion |
|
Verona Pharma PLC ADR
NASDAQ:VRNA
|
USA | $572.87 Million |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA
|
USA | $641.76 Million |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
Hebei Changshan Biochem Pharma
SHE:300255
|
China | CN¥4.66 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF2.64 Billion |
Eterna Therapeutics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.58 | 0.48 | 0.55 |
| Quick Ratio | 1.58 | 0.48 | 0.59 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $1.24 Million | $-5.22 Million | $-1.39 Million |
Eterna Therapeutics Inc - Advanced Valuation Insights
This section examines the relationship between Eterna Therapeutics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.63 |
| Latest Market Cap to Assets Ratio | 1.97 |
| Asset Growth Rate (YoY) | -89.3% |
| Total Assets | $5.27 Million |
| Market Capitalization | $10.38 Million USD |
Valuation Analysis
Above Book Valuation: The market values Eterna Therapeutics Inc's assets above their book value (1.97x), reflecting positive investor sentiment about the company's future prospects.
Significant Asset Reduction: Eterna Therapeutics Inc's assets decreased by 89.3% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Eterna Therapeutics Inc (2006–2024)
The table below shows the annual total assets of Eterna Therapeutics Inc from 2006 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $5.27 Million | -89.28% |
| 2023-12-31 | $49.13 Million | +120.53% |
| 2022-12-31 | $22.28 Million | -29.33% |
| 2021-12-31 | $31.52 Million | +144.27% |
| 2020-12-31 | $12.91 Million | -15.51% |
| 2019-12-31 | $15.28 Million | +2.77% |
| 2018-12-31 | $14.86 Million | -10.30% |
| 2017-12-31 | $16.57 Million | -3.30% |
| 2016-12-31 | $17.14 Million | +1.86% |
| 2015-12-31 | $16.82 Million | -24.45% |
| 2014-12-31 | $22.27 Million | +44.06% |
| 2013-12-31 | $15.46 Million | +22.13% |
| 2012-12-31 | $12.66 Million | +8.66% |
| 2011-12-31 | $11.65 Million | -11.26% |
| 2010-12-31 | $13.12 Million | -8.20% |
| 2009-12-31 | $14.30 Million | +22.59% |
| 2008-12-31 | $11.66 Million | -44.09% |
| 2007-12-31 | $20.86 Million | -21.36% |
| 2006-12-31 | $26.52 Million | -- |
About Eterna Therapeutics Inc
Ernexa Therapeutics Inc., a preclinical-stage company, develops induces derived mesenchymal stem cells (iMSC) therapies for the treatment of solid tumors and autoimmune disease. The company's lead product is ERNA-101, an allogenic pro-inflammatory cytokine (IL-7/IL-15) secreting iMSC for the treatment of ovarian cancer; and ERNA-102, an anti-inflammatory cytokine (IL-10) secreting iMSC for the tr… Read more